- Home
- NBP vs RXST Comparison
NBP vs RXST Comparison
Compare NBP & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | RXST |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 307.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBP | RXST |
|---|---|---|
| Price | $3.11 | $7.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | $9.00 | ★ $11.50 |
| AVG Volume (30 Days) | 432.4K | ★ 821.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | $2.68 |
| Revenue Next Year | N/A | $10.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.03 | $6.62 |
| 52 Week High | $5.19 | $27.13 |
Technical Indicators
Market Signals| Indicator | NBP | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 41.57 |
| Support Level | $3.04 | $7.06 |
| Resistance Level | $3.74 | $9.11 |
| Average True Range (ATR) | 0.20 | 0.55 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 17.78 | 40.57 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.